ALK-Abelló A/S (0OIR)
LSE
Closed
Sep 18, 2026
Day's Range
149.4552 wk Range
149.45Overview - 0OIR - ALK-Abelló A/S
Key Statistics
Valuation
Enterprise Value
17.80B
P/E (Trailing)
123.22
P/E (Forward)
116.70
PEG Ratio
4.92
Price / Sales (TTM)
8.51
Price / Book
10.48
EV / EBITDA
24.45
Profitability
Gross Margin
66.57%
Profit Margin
7.67%
Operating Margin
12.00%
Return on Assets
5.54%
Return on Equity
9.00%
Ownership
Shares Outstanding
221.87M
Float
131.17M
Held by Insiders
0.00%
Held by Institutions
61.24%
Price stats
Beta
0.30
50-Day Avg
150.78
200-Day Avg
151.47
Dividends
Payout Ratio
0.00%
Market Cap - 0OIR - ALK-Abelló A/S
Peers - 0OIR - ALK-Abelló A/S
Peer Comparison
Compared with companies in Biotechnology listed on LSE.
- 0OIRLSEALK-Abelló A/S30.00BMarket Cap+0.00%52-week change123.23P/E (Trailing)7.67%Profit Margin
- 0MGBLSEGenmab A/S168.08BMarket Cap+14.99%52-week change29.66P/E (Trailing)29.01%Profit Margin
- 0QZULSEVertex Pharmaceuticals Incorporated Common Stock129.81BMarket Cap+24.36%52-week change0.54P/E (Trailing)34.99%Profit Margin
- 0R2MLSERegeneron Pharmaceuticals, Inc.84.57BMarket Cap+27.23%52-week change0.11P/E (Trailing)27.86%Profit Margin
- 0A45LSEModerna Inc.70.30BMarket Cap+83.56%52-week change53.96P/E (Trailing)11.32%Profit Margin
- 0QW0LSEargenx SE50.13BMarket Cap+25.52%52-week change40.43P/E (Trailing)-47.51%Profit Margin
- 0NZTLSEUCB SA42.62BMarket Cap+1.46%52-week change123.24P/E (Trailing)6.45%Profit Margin
Profile Summary - 0OIR - ALK-Abelló A/S
About
ALK-Abelló A/S is a Denmark-based global pharmaceutical company specializing in the development, manufacturing, and marketing of products for allergy prevention, diagnosis, and treatment. Founded in 1923 and headquartered in Hørsholm, it pioneered allergy immunotherapy, offering unique vaccination therapies in…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
